ProCE Banner Activity

CE / CME

Atopic Dermatitis in Infants and Young Children: From Disease Presentation to Treatment Sequencing

Clinical Thought

Disease presentation and treatment considerations for atopic dermatitis (AD) in infants and young children are different than managing this disease in adults. Learn how AD presents and what treatment strategies should be considered to improve outcomes among our younger pediatric patients.

Nurse Practitioners/Nurses: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Released: April 22, 2025

Expiration: April 21, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Practicing Clinicians Exchange (PCE)

ProCE Banner
ProCE Banner

Supporters

This educational activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals

Sanofi

Target Audience

This activity is intended for nurse practitioners and physician associates who are involved in the management of children and adults with moderate to severe atopic dermatitis.

Program Learning Goal

The goal of this educational activity is to improve learners’ knowledge, competence, and performance in the management of children and adults with moderate to severe atopic dermatitis. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement patient-reported outcomes into the diagnosis, severity assessment, and treatment decisions for children and adults with moderate to severe AD

  • Develop patient-centered care strategies by involving patients in the long-term management of moderate to severe AD, considering quality of life and functional goals

Disclosure

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Benjamin Ungar, MD: consultant/advisor/speaker: AbbVie, Botanix, Bristol Myers Squibb, Fresenius Kabi, Galderma, Johnson & Johnson, LEO Pharma, Lilly, Pfizer, Primus, Sanofi, UCB; researcher: Arcutis, Incyte, Rapt Therapeutics.

Katie Smiley, PA-C: consultant/advisor/speaker: Adma Biologics, Novartis.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2025, through April 21, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours, including 0.25 hour of pharmacotherapy credits.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until April 21, 2026. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.